Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Silexion Therapeutics Corp

NASDAQ: SLXN · Life Sciences · 9 alerts · CIK 2022416

Share price
$1.76Close, Nov 16
Market cap
$1.14M
Shares outstanding
649.53KLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Silexion Therapeutics Corp filings on SEC EDGAR ↗

6:14 AM ET 8-K
Financial Results

Silexion Therapeutics Financial Results

Silexion Therapeutics reported Q3 2026 financial results, highlighting the dosing of the first patient in its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. The company strengthened its balance sheet through a public offering and warrant inducement, ending the quarter with $4.8 million in cash and $3.0 million in shareholders' equity.

Term
Q3 2026

“In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”

Ilan Hadar, Chairman and Chief Executive Officer

“During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”

Mirit Horenshtein Hadar, Chief Financial Officer
4:43 PM ET 10-Q
Financial Results

Silexion Therapeutics Q3 2026 Results: Net Loss of $2.53M, Loss Narrows

Silexion Therapeutics Corp is a development-stage biotechnology company focused on its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. As of November 12, 2026, the company reported 649,528 ordinary shares outstanding and continues to operate as an emerging growth company with no product revenue to date.

Key figure
Net loss $2.53M
4:13 PM ET 8-K
Reverse Stock Split

Silexion Therapeutics Reverse Stock Split

Silexion Therapeutics Corp effected a 1-for-24 reverse share split of its ordinary shares effective after the close of trading on November 10, 2026. In connection with the split, the company adjusted its outstanding warrants, increasing the exercise price 24-fold to $372,600.00 per post-split share and reducing the number of shares issuable per warrant to 1/24th of a share.

7:27 AM ET 8-K
Reverse Stock Split

Silexion Therapeutics Reverse Stock Split

Silexion Therapeutics announced a 1-for-24 reverse share split of its ordinary shares, effective after the market close on November 10, 2026. The split is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. Trading on a split-adjusted basis will begin on November 11, 2026, under the existing ticker symbol SLXN.

4:05 PM ET 8-K
Reverse Stock Split

Silexion Therapeutics Reverse Stock Split

Silexion Therapeutics Corp shareholders approved a 1-for-24 reverse stock split of the company's ordinary shares, increasing the par value from $0.135 to $3.24 per share. Additionally, shareholders approved an increase in authorized share capital from 15.9 million to 515.9 million ordinary shares. The reverse split and capital increase were finalized at a reconvened extraordinary general meeting on October 26, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.